Authors | Years | N° Patients | Type of Surgery TT+ | Skip metastases | Tumor site | Tumor size | Capsular invasion | |||
---|---|---|---|---|---|---|---|---|---|---|
CND | CND + LND | N° | Upper pole | Middle portion | < 10 | > 10 | ||||
Ducci M | 1997 | 36 | 36 | 50 ispilateral 14 controlateral | 11.1% | NE | NE | NE | NE | NE |
Machens A | 2004 | 215 | 215 | 95.3% ipsilateral 73.5% controlateral | 13 (19.7%) | NS | NS | NS | NS | NS |
Roh JL | 2007 | 22 | 22 | NS | 3 (13,7%) | NE | NE | NE | NE | NE |
Roh JL | 2008 | 52 | 52 | 57 | 5 | NS | NS | NS | NS | NS |
Wada N | 2008 | 231 | 231 | 231 ipsilateral | 17 | NS | NS | NS | NS | NS |
Chung IS | 2009 | 245 | 245 | 39 (12 metastases) | 3 | |||||
Xiao GZ | 2010 | 121 | 121 | 121 | 9 | NS | NS | NS | NS | NS |
Park JH | 2012 | 147 | 147 | 147 | 32 (21.8%) | NS | NS | 32 | NS | NS |
Xiang D | 2015 | 949 | 949 | 44 | 11 | 8 | 3 | NS | NS | NS |
Lei J | 2017 | 450 | 450 | 450 | 39 (8.7%) | 37 (94.9%) | 2 (5.1%) | 71.8% | NS | 84.6% |
Zhan X | 2017 | 272 | TT | NS | 29 (10.7%) | 95% | NS | 95% | NS | NS |
Xlin N | 2017 | 203 | 203 | 203 | 30 (14.8%) | 19 | ||||
Lee B | 2017 | 55 | NS | 55 | 3 | NS | NS | NS | NS | NS |